Blade(BLDE) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, the company reported revenue of $66.8 million, driven by logistics growth, with organic growth of 35.3% to $49.2 million compared to $36.4 million in the prior year [22][24] - Full year 2025 revenue and adjusted EBITDA were $197.1 million and $14.1 million respectively, both exceeding the high end of guidance [22][24] - Adjusted EBITDA rose to $7 million in Q4 2025, up from $1.1 million in the prior year period [25] Business Line Data and Key Metrics Changes - Logistics revenue in Q4 2025 was $49.2 million, reflecting a 35.3% increase year-over-year [22][24] - Clinical revenue was $17.6 million in Q4 2025, significantly up from $2.8 million in Q3 2025, attributed to the Keystone acquisition [22][24] - Gross profit increased 90% to $14.4 million in Q4 2025, with gross margin rising to 21.6% from 20.8% in the prior year [24][25] Market Data and Key Metrics Changes - Approximately 20% of revenue is generated from Organ Procurement Organizations (OPOs), with Tier One OPOs representing 2.4 times the revenue of Tier Three OPOs [10] - The company is well-positioned to benefit from regulatory changes incentivizing the pursuit of medically complex organs, particularly from DCD donors [9][10] Company Strategy and Development Direction - The company is focusing on acquisitions of smaller businesses to accelerate growth and expand geographically [5][6] - A significant part of the strategy includes enhancing the logistics services for transplant clinical cases, which contributed to revenue growth [7][10] - The company plans to maintain an average annualized adjusted EBITDA growth rate of at least 30% over the coming years [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the future, raising guidance for 2026 revenue to $260 million-$275 million and adjusted EBITDA to $29 million-$33 million [27] - The company noted that while there was a soft January for the industry, they have seen continued strength in logistics trips and clinical cases [29][30] - Management is optimistic about the integration of the Keystone acquisition and the positive feedback from customers [30] Other Important Information - The company ended the year with approximately 30 dedicated or owned aircraft and plans to add two new owned aircraft to support new regions [12][13] - The company has a $30 million asset-based credit facility with JPMorgan, providing flexibility for future acquisitions [15] Q&A Session Summary Question: Update on continuous distribution policy and stakeholders involved - Management stated that continuous distribution is still the goal for all organs, with lungs already transitioned, but the timeline for hearts and livers is uncertain due to regulatory focus on other issues [32][33] Question: Breakdown of the transplant value chain and service usage - Management indicated that transplant clinical services have slightly higher profit margins than non-transplant clinical services, with efforts to convert more clinical customers to use logistics services [36][38] Question: Acquisition pipeline and adjacent offerings - The company plans to announce acquisitions as they close and is focused on increasing scale and national footprint through product servicing [41][42] Question: Impact of weather on operations - Management noted that severe weather in the Northeast has caused unusual disruptions, but overall confidence for the year remains strong [71][72] Question: Impact of higher oil prices - Management clarified that fuel price increases would be passed through to customers and would not significantly impact the company's cost structure [73][74]